Nexalin Technology (NASDAQ: NXL; NXLIW) has announced that the United States Patent and Trademark Office (USPTO) has issued a design patent providing 15 years of protection for the company’s next-generation HALO Clarity neuromodulation device.
According to Nexalin, HALO Clarity is designed to deliver non-invasive neuromodulation by stimulating brain structures associated with mental health and neurological conditions—such as Alzheimer’s disease—without reliance of pharmaceuticals or surgery.
In a statement, Mark White, CEO of Nexalin, commented, “This patent represents another important milestone in our mission to transform mental health and neurological care. HALO Clarity is engineered for comfort, usability, and performance to deliver our proprietary DIFS technology—a non-invasive, drug-free approach we believe can meaningfully impact conditions such as depression, anxiety, trauma-related disorders, and neurodegenerative diseases including Alzheimer’s and dementia.”
He added, “Importantly, the system is designed for supervised use from the patient’s home, giving physicians the ability to monitor and guide treatment remotely while offering patients a safe and convenient alternative to in-clinic visits. We believe this unique capability has the potential to expand access, improve compliance, and lower the cost of care for patients worldwide.”
